Localized Prostate Cancer VL

When to Add ADT to Early or Late Salvage Radiation - Dan Spratt

Details
Daniel Spratt, MD, reviews the data from two trials that demonstrate the selection of patients for the addition of hormone therapy (ADT) to post-prostatectomy radiation therapy. Dr. Spratt discusses two phase three trials that have evaluated hormonal therapy in the postoperative RP setting with a rising PSA. The RTOG 9601 trial and the GETUG-AFU 16 trial are distinct from each other where the RTOG...

Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt

Details
Ashley Ross, MD, PhD, Alan Dal Pra, MD, and Daniel Spratt, MD, discuss two cases of patients each about 18 months post-prostatectomy with rising PSA, evaluating the timing to radiotherapy and the evidence to intensify with ADT. Biographies: Ashley Ross, MD, Ph.D., Associate Professor, Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois Alan Dal Pra, MD, A...

Prostate Cancer Screening and Shared Decision Making in the Veterans Health Administration - Stacy Loeb

Details
In this conversation, Mathew Cooperberg and Stacy Loeb discuss recent advances in prostate cancer screening and shared decision making in the Veterans Health Administration (VA). Dr. Loeb highlights findings from a Journal of the National Cancer Institute publication looking at trends of PSA screening in the VA healthcare system and which found a decline in the use of PSA testing among PSA eligibl...

PCORI-Funded Initiative Evidence Gaps To Guide Future Research on the Use of Active Surveillance for Prostate Cancer – M. Minhaj Siddiqu

Details
M Minhaj Siddiqui joins Matthew Cooperberg to highlight the Patient-Centered Outcomes Research Institute (PCORI) grant awarded to researchers at the University of Maryland School of Medicine (UMSOM). The grant supports the initiative to highlight, to a greater extent, the patient's voice in determining the next course of action to chart in the future of active surveillance in the United States. Mo...

Prostate Cancer Modeling: The CISNET Prostate Group - Ruth Etzioni

Details
Ruth Etzioni, PhD joins Matthew Cooperberg, MD MPH in a discussion about the role and history of prostate cancer modeling based upon PSA. Cancer Intervention and Surveillance Modeling Network (CISNET) is a consortium of NCI-sponsored investigators who use simulation modeling to improve our understanding of cancer control interventions in prevention, screening, and treatment and their effects on po...

A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt

Details
Ashley Ross is joined by Daniel Spratt presenting a European Association of Urology publication on A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer . In a field of rapidly acquiring data, among the challenges that motivated this systematic review was the breadth of papers and data being published. Dr. Spratt and colleagues sought to acquire the most up-to-...

Prostate Active Surveillance Study (PASS) - Daniel Lin

Details
The Canary Prostate Active Surveillance Study (PASS) is a multi-center research study for men who have chosen active surveillance to manage their prostate cancer. Canary is the world’s only non-profit focused solely on early cancer detection. Active surveillance in PASS means closely monitoring men with prostate cancer and offering treatment if test results show the cancer is getting worse. This i...

How Can We Accelerate Clinical Trial Accrual in Localized Prostate Cancer? - Brian F. Chapin

Details
Brian Chapin, MD, joins Matthew Cooperberg, MD, MPH, FACS, in conversation discussing conceiving and executing large phase III trials focused on the management of localized prostate cancer. Dr. Chapin highlights what it takes to get one of these trials off the ground and what the future of trials looks like for men with localized disease. He specifically highlights the actively recruiting Phase II...

An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener

Details
Historically called Gleason 6, and more recently referred to as Grade Group 1, is a term that started in the 1960s with Don Gleason's original description. It was more universally adopted by the late 1980s, and the Grade Group system was initiated in 2014. In this conversation with Matthew Cooperberg, MD, MPH, FACS, Scott Eggener, MD offers his perspective on the importance of understanding Gleaso...

DASL-HiCAP (ANZUP1801): The Impact of Darolutamide on Standard Therapy for Localized Very High-risk Cancer of the Prostate - Christopher Sweeney

Details
Christopher Sweeney, MD, sits down with Alicia Morgans, MD, MPH to discuss “DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Prostate Cancer,” a phase 3, 1100 patient study lead by the ANZUP group which randomizes men with high-risk prostate cancer to darolutamide or standard of care. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical Scho...
email news signup